Stock listing

BSE:MARKSANS Marksans Pharma Limited Share Price

Indian listing (BSE) of Marksans Pharma Limited · home listing NSE:MARKSANS

Follow Marksans Pharma Limited into a list and get an email when it puts out news.

Home listing price · NSE:MARKSANS

₹291.15 INR -3.35 (-1.1%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NSE:MARKSANS

Past year +50.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₹288.40 – ₹297.20 INRNov 20, 2026
Volume
907,580 sharesNov 20, 2026
Market cap
₹132.0B INRAt the close on Nov 20, 2026 · price × 453.2M shares outstanding
52-week range
₹155.00 – ₹350.95 INRLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₹580.4M INRMedian day 1.46M shares · 3 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Marksans Pharma Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NSE:MARKSANS · Home₹291.15 INR-3.35 (-1.1%)907,580₹296.00₹297.20₹288.40₹294.50Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NSE:MARKSANS · INR, adjusted for splits

DayCloseChange%OpenHighLowVolume
₹291.15-3.35-1.1%₹296.00₹297.20₹288.40907,580
₹294.50-11.60-3.8%₹306.20₹315.55₹291.301,414,007
₹306.10-3.10-1.0%₹307.90₹309.20₹302.00899,969
₹309.20-9.30-2.9%₹318.50₹318.90₹307.651,184,443
₹318.50-1.50-0.5%₹323.70₹328.70₹315.501,738,972
₹320.00+13.45+4.4%₹306.00₹322.95₹305.852,088,557
₹306.55-2.20-0.7%₹310.00₹310.45₹303.051,216,362
₹308.75+5.05+1.7%₹305.60₹313.50₹305.20823,630
₹303.70-10.05-3.2%₹312.50₹313.00₹301.851,341,800
₹313.75+12.10+4.0%₹307.00₹316.25₹300.352,103,185
₹301.65-13.65-4.3%₹316.90₹327.00₹296.605,960,208
₹315.30+3.00+1.0%₹315.50₹317.95₹312.00786,626
₹312.30+6.10+2.0%₹306.90₹314.50₹305.90835,052
₹306.20-9.15-2.9%₹317.00₹317.35₹304.901,208,920
₹315.35+10.15+3.3%₹305.90₹318.80₹300.002,008,651
₹305.20+5.10+1.7%₹301.10₹308.25₹298.651,405,300
₹300.10+3.45+1.2%₹297.60₹303.10₹294.801,026,423
₹296.65+9.75+3.4%₹286.90₹298.75₹285.101,170,447
₹286.90-7.55-2.6%₹292.00₹295.35₹282.701,414,458
₹294.45-3.70-1.2%₹294.00₹298.00₹291.25817,786
₹298.15-4.90-1.6%₹304.65₹306.75₹293.601,385,441
₹303.05-7.95-2.6%₹311.00₹314.50₹302.00817,392
₹311.00+3.15+1.0%₹308.10₹313.50₹306.00767,998
₹307.85-6.30-2.0%₹314.20₹315.10₹306.55681,887
₹314.15-3.10-1.0%₹315.00₹320.90₹312.35592,331
₹317.25+0.85+0.3%₹316.95₹318.00₹309.801,011,092
₹316.40+7.30+2.4%₹310.00₹318.00₹309.00822,584
₹309.10+1.30+0.4%₹308.50₹316.40₹308.001,140,146
₹307.80-17.65-5.4%₹326.10₹326.25₹304.452,348,179
₹325.45+1.05+0.3%₹325.80₹329.00₹318.452,155,353
₹324.40-7.25-2.2%₹332.75₹341.95₹322.203,112,693
₹331.65+6.05+1.9%₹327.20₹333.00₹324.601,566,583
₹325.600.000.0%₹325.60₹325.60₹325.600
₹325.60+3.30+1.0%₹322.05₹332.50₹318.152,445,782
₹322.30-20.45-6.0%₹344.00₹345.90₹321.003,253,271
₹342.75+11.20+3.4%₹333.00₹347.40₹332.954,594,619
₹331.55-5.40-1.6%₹335.40₹341.00₹329.001,876,478
₹336.95-0.45-0.1%₹337.50₹341.95₹331.851,452,979
₹337.40-10.20-2.9%₹345.80₹350.95₹336.152,858,544
₹347.60+14.65+4.4%₹332.95₹348.95₹331.003,317,178
₹332.95-5.15-1.5%₹340.05₹340.95₹328.651,560,912
₹338.10+17.95+5.6%₹322.20₹339.00₹321.203,189,102
₹320.15+0.45+0.1%₹321.35₹325.85₹318.65975,318
₹319.70+3.25+1.0%₹315.95₹322.50₹312.951,104,335
₹316.45+3.60+1.2%₹311.80₹323.60₹307.052,264,075
₹312.85-16.55-5.0%₹330.00₹331.40₹301.102,298,117
₹329.400.000.0%₹329.40₹329.40₹329.400
₹329.40-1.00-0.3%₹325.00₹333.75₹324.201,631,814
₹330.40+0.25+0.1%₹329.00₹334.55₹323.801,295,256
₹330.15-5.75-1.7%₹336.00₹340.00₹328.651,784,442
₹335.90+9.15+2.8%₹337.50₹349.95₹331.605,090,238
₹326.750.000.0%₹326.75₹326.75₹326.750
₹326.75-5.45-1.6%₹333.00₹335.45₹323.451,654,370
₹332.20-0.30-0.1%₹334.30₹341.00₹331.002,726,464
₹332.50+10.10+3.1%₹321.20₹337.65₹318.756,573,003
₹322.40+0.80+0.2%₹322.90₹324.70₹315.501,408,843
₹321.60-8.10-2.5%₹328.10₹329.90₹313.102,486,251
₹329.70+3.55+1.1%₹326.15₹335.45₹324.051,463,661
₹326.15-4.90-1.5%₹332.00₹332.95₹323.051,415,329
₹331.05+12.55+3.9%₹319.95₹332.40₹319.201,989,892
₹318.50-5.40-1.7%₹326.30₹330.75₹315.101,686,249
₹323.90+2.60+0.8%₹322.60₹325.50₹317.901,794,290
₹321.30+0.45+0.1%₹320.85₹327.00₹313.852,597,073
₹320.85-6.15-1.9%₹328.50₹328.55₹318.501,960,211

Splits

1 split · NSE:MARKSANS · every price before a split is adjusted for it

DayRatioWhat
10-for-1Split
Ticker
BSE:MARKSANS
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
BSE
Currency
INR

What changed lately

Latest news

All Marksans Pharma Limited news

Marksans Pharma Limited on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
7 in the last 12 months · 77 in all · newest Nov 4, 2026 · oldest 2020
Decks
33 decks · latest Nov 4, 2026

Where Marksans Pharma Limited is listed

ListingExchangeCountryCurrency
NSE:MARKSANS · Home listingNSEIndiaINR
BSE:MARKSANS · This pageBSEIndiaINR

Valuation

P/E 23.6× against a median of 42.0×: 3rd lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
₹125.4B INR
P/E
23.6×
EV/sales
3.7×
EV/EBITDA
16.0×
Price/book
4.0×
Gross margin
41.0%
Operating margin
20.0%
Net margin
16.5%
Debt to equity
0.1×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Marksans Pharma Limited · NSE:MARKSANSUS$1.42BUS$1.35B23.6×3.7×16.0×4.0×16.5%0.1×n/a
Yifan Pharmaceutical Co., Ltd. Class A · SZSE:002019US$1.52BUS$1.60B32.6×2.2×n/a1.1×6.3%0.2×n/a
Precigen, Inc. · NASDAQ:PGENUS$1.51BUS$1.56B61.9×9.9×40.9×18.0×15.6%1.1×1.46
Corona Remedies Limited · NSE:CORONAUS$1.49BUS$1.48B74.8×9.8×46.7×17.2×13.2%0.0×n/a
Sunshine Lake Pharma Co., Ltd. Class H · HKEX:6887US$1.48BUS$1.48B36.2×2.0×9.0×2.5×5.7%0.4×n/a
Zhejiang Medicine Co., Ltd. Class A · SSE:600216US$1.47BUS$973.2M15.5×0.8×n/a0.8×7.5%0.0×n/a
Yantai Dongcheng Biochemicals Co., Ltd. Class A · SZSE:002675US$1.46BUS$1.41B46.5×3.6×n/a2.2×8.0%0.1×n/a
Fujian Haixi Pharmaceuticals Co., Ltd. Class H · HKEX:2637US$1.45BUS$1.27B54.6×14.6×41.3×5.8×30.4%0.0×n/a
Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A · SZSE:002020US$1.40BUS$1.23B13.2×2.0×n/a1.6×17.5%0.0×n/a
Chengdu Olymvax Biopharmaceuticals Inc. Class A · SSE:688319US$1.37BUS$1.39Bn/a11.7×n/a10.2×−4.0%0.4×n/a
Celltrion Pharm Inc. · KRX:068760US$1.34BUS$1.25B42.0×2.9×19.6×4.0×7.4%0.0×n/a
Median of the othersUS$1.46BUS$1.40B42.0×3.2×40.9×3.3×7.7%0.1×1.46

Forecasts

Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
322.33 INR · Analysts' mean
EPS, year to Mar 2027
12.70 · 2 analysts
Revenue, year to Mar 2027
36.48B · 2 analysts

Team and board

Officers

OfficerRole
Mark SaldanhaChairman & Managing Director

Board

DirectorRole
Abhinna Sundar MohantyIndependent Director
Digant Mahesh ParikhIndependent Director
Sandra SaldanhaWhole-time Director
Shailaja VardhanIndependent Director
Srinivas MishraIndependent Director
Sunny SharmaNon-executive Director
Varddhman V. JainWhole-time Director

Events

QuarterResultsShare move
Q2 2027Nov 4, 2026 · Before open−4.3%
Q1 2027Aug 12, 2026 · Before open+12.1%
Q4 2026May 26, 2026 · Before open+15.7%
Q3 2026Feb 5, 2026 · Before open+1.4%
Q3 2024Feb 13, 2024 · Before open+7.8%

Open Events

Decks

DeckKindSlidesDate
Q2 FY27 Earnings PresentationEarnings54 slidesNov 4, 2026
Q1 FY27 Earnings PresentationEarnings51 slidesAug 12, 2026
Q4 FY26 Earnings PresentationEarnings56 slidesMay 26, 2026
Q3 FY2026 Earnings PresentationEarnings48 slidesFeb 5, 2026
Q2 FY26 Earnings PresentationEarnings49 slidesNov 13, 2025
Q1 FY2026 Earnings PresentationEarnings48 slidesAug 12, 2025
Q1 FY2026 Earnings PresentationEarnings47 slidesAug 12, 2025
Q4 FY25 Earnings PresentationEarnings52 slidesMay 19, 2025
Q3 FY25 Earnings PresentationEarnings48 slidesFeb 11, 2025
H1 FY25 Earnings PresentationEarnings49 slidesNov 12, 2024
All 33 decks
DeckKindSlidesDate
Q1 FY2025 Earnings PresentationEarnings51 slidesAug 13, 2024
Q4 FY2024 Earnings PresentationEarnings33 slidesMay 30, 2024
Q3 FY2024 Earnings PresentationEarnings31 slidesFeb 13, 2024
Q2 FY24 Earnings PresentationEarnings32 slidesNov 9, 2023
Q1 FY2024 Earnings PresentationEarnings29 slidesAug 11, 2023
Q4 FY2023 Earnings PresentationEarnings81 slidesMay 30, 2023
Q3 FY2023 Earnings PresentationEarnings84 slidesFeb 13, 2023
Q2 FY23 Earnings PresentationEarnings84 slidesNovember 2022
Q1 FY2023 Earnings PresentationEarnings77 slidesJune 2022
Q4 & FY2022 Earnings PresentationEarnings44 slidesMay 30, 2022
Q3 FY2022 Earnings PresentationEarnings38 slidesFeb 11, 2022
H1 FY22 Earnings PresentationEarnings38 slidesNov 10, 2021
Q1 FY2022 Earnings PresentationEarnings44 slidesAug 11, 2021
Q4 FY2021 Earnings PresentationEarnings43 slidesMay 31, 2021
Q3 FY2021 Earnings PresentationEarnings41 slidesFeb 8, 2021
H1 FY21 Earnings PresentationEarnings34 slidesNov 6, 2020
Q1 FY2021 Earnings PresentationEarnings34 slidesAug 4, 2020
FY2020 Earnings PresentationEarnings34 slidesJun 2, 2020
Q3 FY2020 Earnings PresentationEarnings34 slidesFeb 11, 2020
Q2 FY20 Earnings PresentationEarnings33 slidesNov 12, 2019
Q1 FY20 Earnings PresentationEarnings34 slidesAug 9, 2019
Investor Presentation (October 2014)Investor deck21 slidesOctober 2014
Investor Presentation (January 2014)Investor deck43 slidesJanuary 2014

Open Decks

Financials

Annual, in INR

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue29.5B26.2B21.8B18.5B14.8B13.7B11.3B9.87B9.13B7.67B
Cost of revenue17.9B11.4B10.7B9.21B7.48B6.19B5.68B5.17B5.48B4.72B
Gross profit11.6B14.8B11.0B9.31B7.32B7.50B5.61B4.70B3.65B2.95B
Research and development230.6M158.9M192.5M128.7M83.1M57.1M52.7M45.3M
Selling, general and administrative2.87B245.7M177.0M162.6M248.0M238.8M179.7M232.0M206.3M192.0M
Operating income5.05B11.3B3.87B3.00B5.17B5.48B1.70B1.09B516.0M155.3M
Depreciation and amortization986.3M833.9M742.7M518.5M447.8M361.5M266.6M228.0M268.4M300.9M
EBITDA6.03B12.1B4.62B3.52B5.62B5.84B1.97B1.32B784.4M456.2M
Interest expense241.3M116.6M112.0M91.3M84.5M79.9M87.5M96.6M102.2M67.9M
Income before tax5.61B5.04B4.24B3.38B2.48B3.02B1.57B1.04B498.0M155.3M
Income tax1.40B1.21B1.09B723.3M607.0M636.3M364.2M238.7M140.0M35.1M
Net income4.18B3.81B3.14B2.66B1.85B2.39B1.21B804.4M329.4M95.2M
Earnings per share, basic9.228.406.926.414.515.832.951.970.800.23

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents6.34B4.96B4.03B3.82B3.46B2.09B931.2M328.5M397.2M251.6M
Short-term investments3.55B2.09B2.97B3.33B1.40B17.2M17.2M500.0K897.1K
Receivables6.45B5.42B4.59B4.20B3.96B2.77B2.43B1.84B1.83B2.48B
Inventory9.72B8.46B6.18B4.85B4.24B4.04B2.42B2.93B2.18B1.90B
Current assets27.2B22.0B18.6B16.8B12.0B9.02B5.90B5.31B4.49B4.84B
Property, plant and equipment8.95B3.87B3.42B2.54B2.30B1.98B1.86B1.65B
Goodwill452.6M409.3M395.0M384.9M300.3M195.9M243.8M314.5M617.5M696.8M
Total assets38.6B32.4B26.8B21.9B16.4B12.3B8.97B8.04B7.29B7.52B
Accounts payable3.37B3.06B2.68B2.31B2.00B1.69B1.10B1.06B674.8M1.62B
Current liabilities5.27B4.77B3.90B3.41B3.56B2.98B2.20B2.33B2.33B3.01B
Long-term debt050.0M50.0M100.0M100.0M110.0M
Total debt3.43B3.22B2.44B1.23B1.11B391.0M296.5M1.10B1.28B1.21B
Total liabilities8.08B7.50B5.95B4.25B4.17B3.23B2.48B2.51B2.49B3.01B
Shareholders' equity30.2B24.7B20.7B17.5B12.0B8.86B6.36B5.42B4.71B4.45B
Shares outstanding453.3M453.1M453.2M415.4M409.3M409.3M409.3M409.3M409.3M409.3M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations4.82B2.07B2.30B2.37B992.6M1.79B2.10B274.0M589.2M88.4M
Capital spending-1.31B-1.73B-2.09B-536.3M-463.3M-464.2M-596.3M-131.5M-389.4M-277.5M
Free cash flow3.51B337.4M215.7M1.84B529.3M1.32B1.50B142.5M199.9M-189.1M
Cash from investing-2.75B-490.1M-1.41B-2.59B-416.9M-449.0M-595.8M-134.8M-387.8M-208.4M
Cash from financing-681.4M-651.5M-687.3M1.98B795.1M-152.9M-901.5M-207.8M-54.3M18.6M
Dividends paid-362.5M-271.9M-226.6M-101.7M-105.8M-40.9M-295.0M-44.4M-24.6M-145.3M
Share buybacks0-451.7M-451.7M-911.5M-50.0M-50.0M-10.0M-15.0M
Change in cash4.93B925.1M208.4M1.76B1.37B1.19B602.7M-68.6M147.1M-101.4M

Open Financials

Filings

FilingDateTypeFiled with
Marksans Pharma Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press release dated 4 November 2026 regarding unaudited financial results for the quarter and half year ended 30 September 2026.".Nov 4, 2026ResultsNSE India
Marksans Pharma Limited Press Release Aug 12 2026Aug 12, 2026ResultsNSE India
Marksans Pharma Limited Press Release Jul 08 2026Jul 8, 2026Acquisition or disposalNSE India
Press Release Jun 01 2026May 31, 2026Acquisition or disposalNSE India
Press Release May 26 2026May 26, 2026ResultsNSE India
Press Release Apr 01 2026Apr 1, 2026Operations updateNSE India
Press Release Feb 05 2026Feb 5, 2026ResultsNSE India
Press Release Nov 20 2025Nov 20, 2025Other filingsNSE India
Press Release Nov 19 2025Nov 19, 2025Operations updateNSE India
Press Release Nov 17 2025Nov 17, 2025Other filingsNSE India
All 72 filings
FilingDateTypeFiled with
Press Release Nov 13 2025Nov 13, 2025ResultsNSE India
Press Release Nov 10 2025Nov 10, 2025Other filingsNSE India
Marksans Pharma Limited Press Release Nov 05 2025Nov 4, 2025Operations updateNSE India
Press Release Oct 15 2025Oct 15, 2025Other filingsNSE India
Press Release Sep 23 2025Sep 23, 2025Other filingsNSE India
Press Release Aug 18 2025Aug 18, 2025Other filingsNSE India
Press Release Aug 12 2025Aug 12, 2025Quarterly reportNSE India
Press Release Aug 08 2025Aug 8, 2025Other filingsNSE India
Press Release Jun 30 2025Jun 30, 2025Other filingsNSE India
Marksans Pharma Limited Press Release Jun 19 2025Jun 18, 2025Other filingsNSE India
Marksans Pharma Limited Press Release May 30 2025May 29, 2025Other filingsNSE India
Press Release May 19 2025May 19, 2025Other filingsNSE India
Marksans Pharma Limited Press Release May 15 2025May 14, 2025Other filingsNSE India
Press Release Apr 28 2025Apr 28, 2025Other filingsNSE India
Press Release Mar 20 2025Mar 20, 2025Operations updateNSE India
Press Release Mar 19 2025Mar 19, 2025Other filingsNSE India
Press Release Feb 25 2025Feb 25, 2025Other filingsNSE India
Press Release (Revised) Feb 11 2025Feb 11, 2025ResultsNSE India
Press Release Feb 11 2025Feb 11, 2025ResultsNSE India
Press Release Nov 22 2024Nov 22, 2024Operations updateNSE India
Press Release Nov 12 2024Nov 12, 2024ResultsNSE India
Press Release Aug 21 2024Aug 21, 2024Operations updateNSE India
Press Release Aug 20 2024Aug 20, 2024Operations updateNSE India
Press Release Aug 13 2024Aug 13, 2024Quarterly reportNSE India
Press Release Aug 02 2024Aug 2, 2024Other filingsNSE India
Press Release Jul 02 2024Jul 2, 2024Operations updateNSE India
Press Release May 30 2024May 30, 2024ResultsNSE India
Press Release May 28 2024May 28, 2024Other filingsNSE India
Press Release Apr 18 2024Apr 18, 2024Legal or regulatory actionNSE India
Press Release Feb 13 2024Feb 13, 2024ResultsNSE India
Press Release Nov 09 2023Nov 9, 2023Other filingsNSE India
Press Release Nov 06 2023Nov 6, 2023Operations updateNSE India
Press Release Nov 03 2023Nov 3, 2023Other filingsNSE India
Press Release Nov 01 2023Nov 1, 2023Operations updateNSE India
Press Release Oct 03 2023Oct 3, 2023Operations updateNSE India
Press Release Aug 22 2023Aug 22, 2023Operations updateNSE India
Press Release Aug 11 2023Aug 11, 2023Quarterly reportNSE India
Press Release Aug 07 2023Aug 7, 2023Operations updateNSE India
Press Release Jul 12 2023Jul 12, 2023Operations updateNSE India
Press Release May 30 2023May 30, 2023ResultsNSE India
Press Release Apr 19 2023Apr 19, 2023Other filingsNSE India
Press Release Mar 10 2023Mar 10, 2023Other filingsNSE India
Press Release Feb 13 2023Feb 13, 2023Other filingsNSE India
Press Release Jan 23 2023Jan 23, 2023Operations updateNSE India
Marksans Pharma Limited Press Release Jan 20 2023Jan 19, 2023Other filingsNSE India
Press Release Nov 14 2022Nov 14, 2022Other filingsNSE India
Press Release Oct 11 2022Oct 11, 2022Other filingsNSE India
Press Release Aug 13 2022Aug 13, 2022Other filingsNSE India
Press Release Jul 21 2022Jul 21, 2022Operations updateNSE India
Press Release Jun 21 2022Jun 21, 2022Other filingsNSE India
Press Release Apr 25 2022Apr 25, 2022Acquisition or disposalNSE India
Press Release Feb 22 2022Feb 22, 2022Operations updateNSE India
Press Release Jan 11 2022Jan 11, 2022Operations updateNSE India
Press Release Dec 09 2021Dec 9, 2021Operations updateNSE India
Press Release Nov 10 2021Nov 10, 2021Other filingsNSE India
Press Release Aug 26 2021Aug 26, 2021Other filingsNSE India
Press Release Aug 11 2021Aug 11, 2021Other filingsNSE India
Press Release Jul 10 2021Jul 10, 2021Other filingsNSE India
Press Release May 31 2021May 31, 2021Other filingsNSE India
Press Release Nov 06 2020Nov 6, 2020Other filingsNSE India
Press Release Oct 03 2020Oct 3, 2020Other filingsNSE India
Press Release Aug 04 2020Aug 4, 2020ResultsNSE India

Open Filings

Cap table

Built by 6ix from Marksans Pharma Limited’s releases

Common shares
453,219,996
Fully diluted
453,219,996

Fully diluted

LineShares
Common shares453,219,996

Share count over time

CountShares
Nov 22, 2026453,219,996

Open Cap table

Shareholders

HolderSharesValueAs of
State Street(R) SPDR(R) Portfolio Emerging Markets ETF3.34MUS$9.61MJun 30, 2026
Vanguard Total International Stock Index Fund3.14MUS$8.51MJul 31, 2026
Vanguard Emerging Markets Stock Index Fund3.05MUS$8.27MJul 31, 2026
iShares Core MSCI Emerging Markets ETF2.09MUS$5.4MMay 31, 2026
Emerging Markets Core Equity 2 Portfolio1.89MUS$5.11MJul 31, 2026
Dimensional Emerging Markets Value Fund930KUS$2.51MJul 31, 2026
Vanguard Ftse All-World Ex-Us Small-Cap Index Fund845KUS$2.29MJul 31, 2026
The Emerging Markets Small Cap Series632KUS$1.71MJul 31, 2026
iShares MSCI India Small-Cap ETF408KUS$1.06MMay 31, 2026
WisdomTree India Earnings Fund391KUS$1.13MJun 30, 2026
All 34 holders
HolderSharesValueAs of
Dimensional Emerging Markets Core Equity 2 ETF351KUS$950KJul 31, 2026
Dimensional Emerging Core Equity Market ETF214KUS$580KJul 31, 2026
Avantis Emerging Markets Equity ETF184KUS$475KMay 31, 2026
College Retirement Equities Fund - Total Global Stock Account176KUS$507KJun 30, 2026
Fidelity Total International Index Fund171KUS$464KJul 31, 2026
Vanguard Total World Stock Index Fund154KUS$417KJul 31, 2026
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF147KUS$425KJun 30, 2026
State Street(R) SPDR(R) S&P(R) Emerging Asia Pacific ETF132KUS$380KJun 30, 2026
Dimensional World ex. U.S. Core Equity 2 ETF123KUS$332KJul 31, 2026
Avantis Emerging Markets Value ETF83,831US$217KMay 31, 2026
World ex U.S. Core Equity Portfolio74,161US$200KJul 31, 2026
Emerging Markets Sustainability Core 1 Portfolio60,249US$163KJul 31, 2026
World ex U.S. Targeted Value Portfolio59,055US$160KJul 31, 2026
Emerging Markets ex China Core Equity Portfolio58,282US$158KJul 31, 2026
Emerging Markets Targeted Value Portfolio51,545US$139KJul 31, 2026
Avantis Emerging Markets Equity Fund42,291US$109KMay 31, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio38,479US$111KJun 30, 2026
Vanguard ESG International Stock ETF36,440US$94,315May 31, 2026
Dimensional Emerging Markets Value ETF33,891US$91,765Jul 31, 2026
Dimensional Emerging Markets Sustainability Core 1 ETF18,048US$48,868Jul 31, 2026
Dimensional Emerging Markets ex China Core Equity ETF11,710US$31,707Jul 31, 2026
Avantis Emerging Markets Small Cap Equity ETF11,289US$29,218May 31, 2026
Dimensional World ex U.S. Sustainability Targeted Value Portfolio11,177US$30,216Jul 31, 2026
Avantis Emerging Markets ex-China Equity ETF3,171US$8,207May 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Abhinna Sundar MohantyIndependent Director · Since at least Nov 4, 2026
Digant Mahesh ParikhIndependent Director · Since at least Nov 4, 2026
Mark SaldanhaChairman & Managing Director · Since at least Nov 4, 2026
Sandra SaldanhaWhole-time Director · Since at least Nov 4, 2026
Shailaja VardhanIndependent Director · Since at least Nov 4, 2026
Srinivas MishraIndependent Director · Since at least Nov 4, 2026
Sunny SharmaNon-executive Director · Since at least Nov 4, 2026
Varddhman V. JainWhole-time Director · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Marksans Pharma Limited.